Abstract
Cilostazol was associated with less postoperative carotid stent restenosis, with no statistically significant difference in ischemic stroke and all-cause mortality.
Introduction
Carotid artery stenting (CAS) has become a cornerstone in the management of carotid artery stenosis to prevent ischemic stroke. Despite its efficacy, in-stent restenosis (ISR) remains a significant clinical challenge, affecting over 10% of patients. While standard dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is routine, it often fails to prevent the intimal hyperplasia and smooth muscle cell proliferation that drive ISR. Cilostazol, a phosphodiesterase inhibitor with antiplatelet and antiproliferative properties, has emerged as a potential adjunct therapy to mitigate this risk.
Methods and Study Selection
The researchers conducted a systematic review and meta-analysis following PRISMA guidelines, searching major databases including PubMed, Embase, and the Cochrane Library for studies published through December 2024. The analysis included both randomized controlled trials (RCTs) and non-randomized clinical studies comparing cilostazol-based regimens against standard antiplatelet therapy.
A total of 9 studies involving 1,975 patients were identified. Quality was assessed using the Revised Cochrane Risk of Bias tool (RoB 2.0) for RCTs and the ROBINS-I tool for non-RCTs. Statistical synthesis was performed using RevMan 5.4, employing a random-effects model to calculate Odds Ratios (OR) and 95% confidence intervals (CI).
Key Results
The primary finding of this meta-analysis is that cilostazol significantly reduces the risk of ISR. Patients receiving cilostazol had a 73% lower odds of developing restenosis compared to control groups (OR = 0.27, 95% CI: 0.13–0.54, P < 0.01).
Subgroup analysis revealed that the effect was particularly robust in non-RCTs (OR = 0.17). While the RCT subgroup also showed a favorable trend (OR = 0.38), it did not reach independent statistical significance, likely due to smaller sample sizes in the individual trials. Importantly, the addition of cilostazol did not significantly impact the rates of ischemic stroke (OR = 0.83) or all-cause mortality (OR = 0.53), suggesting a favorable safety profile regarding major adverse events.
Discussion and Biological Mechanisms
Cilostazol’s efficacy in preventing ISR likely stems from its pleiotropic effects. Beyond simple antiplatelet activity, it upregulates tumor suppressor genes such as P53 and P21, which inhibit the proliferation of vascular smooth muscle cells—the primary biological driver of intimal hyperplasia. Additionally, the study noted that cilostazol might be especially beneficial for patients with "closed-cell" stents, which are more prone to inducing localized vascular inflammation.
Limitations and Conclusion
Despite the promising results, several limitations persist. All included studies were conducted in Asian populations, which may limit the generalizability of the findings to other ethnic groups due to genetic variations in drug metabolism (e.g., CYP2C19 polymorphisms). Furthermore, the total sample size remains relatively modest, and there was significant heterogeneity in follow-up duration and stent types.
In conclusion, cilostazol appears to be an effective and safe adjunct therapy for reducing ISR after carotid artery stenting. Future large-scale, international RCTs are necessary to confirm these benefits across diverse global populations and to establish optimal treatment durations.
Summary updated